Oncology Reviews

395 papers and 4.7k indexed citations i.

About

The 395 papers published in Oncology Reviews in the last decades have received a total of 4.7k indexed citations. Papers published in Oncology Reviews usually cover Oncology (160 papers), Molecular Biology (115 papers) and Pulmonary and Respiratory Medicine (102 papers) specifically the topics of Cancer Treatment and Pharmacology (22 papers), Cancer Genomics and Diagnostics (22 papers) and Breast Cancer Treatment Studies (17 papers). The most active scholars publishing in Oncology Reviews are Nuri Faruk Aykan, Shahindokht Bassiri‐Jahromi, Nadine Saraiva, Kátia Ladeira, Filipa Macedo, Francisco Gonçalves, Luísa Pinto, Nuno Bonito, Luis Mendoza and Nithya Jagannathan.

In The Last Decade

Fields of papers published in Oncology Reviews

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Oncology Reviews. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Oncology Reviews

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Oncology Reviews. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Oncology Reviews with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025